EMEA-002333-PIP02-19 - paediatric investigation plan
2-[[2-ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl](methyl)amino]-4-(4-fluorophenyl)-1,3-thiazole-5-carbonitrile
PIPHuman
Galapagos NV
Tel. +32 15342900
E-mail: medicalinfo@glpg.com
P/0148/2020: EMA decision of 18 April 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 2-[[2-ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]...